The Emergent Phenomenon of Aspirin Resistance: Insights from Genetic Association Studies

References

• Agundez JA , MartínezC , Pérez-SalaD , CarballoM , TorresMJ , García-MartínE. Pharmacogenomics in aspirin intolerance. Curr. Drug Metab.10(9), 998–1008 (2009).
   PubMed Web of Science ®Google Scholar
• Floyd CN , FerroA. Mechanisms of aspirin resistance. Pharmacol. Ther.141(1), 69–78 (2014).
   PubMed Web of Science ®Google Scholar
• Patrono C . Aspirin. In: Platelets. Academic Press, MA, USA, 921–936 (2019).
   Google Scholar
• Goodman T , FerroA , SharmaP. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br. J. Clin. Pharmacol.66(2), 222–232 (2008).
   PubMed Web of Science ®Google Scholar
• Cannon CP , CannonPJ. COX-2 inhibitors and cardiovascular risk. Science336(6087), 1386–1387 (2012).
   PubMed Web of Science ®Google Scholar
• Vane J , BakhleY , BottingR. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol.38(1), 97–120 (1998).
   PubMed Web of Science ®Google Scholar
• Undas A , Brummel-ZiedinsK , MannK. Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J. Thromb. Haemost.12(11), 1776–1787 (2014).
   PubMed Web of Science ®Google Scholar
• Patrono C , GarcíaRodríguez LA , LandolfiR , BaigentC. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med.353(22), 2373–2383 (2005).
   PubMed Web of Science ®Google Scholar
• Petrenas LC , YuberoCG. Resistance to aspirin: prevalence, mechanisms of action and association with thromboembolic events. a narrative review. Farm. Hosp.34(1), 32–43 (2010).
   PubMedGoogle Scholar
• Freitas-Silva M , GonçalvesL , MedeirosR , NunesJP. Can the previous therapeutic control of the main risk factors of cerebrovascular disease influence the acetylsalicylic acid–nonresponsive status in acute ischemic stroke patients? Results from a portuguese prospective cohort study. J. Stroke Cerebrovasc. Dis.24(6), 1383–1389 (2015).
   PubMed Web of Science ®Google Scholar
• Baigent C , BlackwellL , CollinsRet al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet373, 1849–1860 (2009).
   PubMed Web of Science ®Google Scholar
• Cai G , ZhouW , LuY , ChenP , LuZ , FuY. Aspirin resistance and other aspirin-related concerns. Neurol. Sci.37(2), 181–189 (2016).
   PubMed Web of Science ®Google Scholar
• Patrono C , BaigentC. Role of aspirin in primary prevention of cardiovascular disease. Nat. Rev. Cardiol.16(11), 675–686 (2019).
   PubMed Web of Science ®Google Scholar
• Ma J , CaiZ , WeiH , LiuX , ZhaoQ , ZhangT. The anti-tumor effect of aspirin: what we know and what we expect. Biomed. Pharmacother.95, 656–661 (2017).
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C , AllenC , BarberRMet al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol.3(4), 524–548 (2017).
   PubMed Web of Science ®Google Scholar
• Krstic MN , MijacDD , PopovicDD , MarkovicAP , MilosavljevićT. General aspects of primary cancer prevention. Dig. Dis.37(5), 406–415 (2019).
   PubMed Web of Science ®Google Scholar
• Cook NR , LeeI-M , ZhangSM , MoorthyMV , BuringJE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann. Intern. Med.159(2), 77–85 (2013).
   PubMed Web of Science ®Google Scholar
• Van Kruijsdijk RC , VisserenFL , RidkerPMet al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart101(5), 369–376 (2015).
   PubMed Web of Science ®Google Scholar
• Vaughan LE , PrizmentA , BlairCK , ThomasW , AndersonKE. Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women’s Health Study. Cancer Causes Control.27(11), 1395–1402 (2016).
   PubMed Web of Science ®Google Scholar
• Cook NR , LeeI-M , ZhangSM , MoorthyMV , BuringJE. Alternate-day low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann. Intern. Med.159(2), 77 (2013).
   PubMed Web of Science ®Google Scholar
• Rothwell PM , WilsonM , ElwinC-Eet al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet376(9754), 1741–1750 (2010).
   PubMed Web of Science ®Google Scholar
• Thorat MA , CuzickJ. Role of aspirin in cancer prevention. Curr. Oncol. Rep.15(6), 533–540 (2013).
   PubMed Web of Science ®Google Scholar
• Pereira C , SousaH , FerreiraPet al. 765G> C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J. Gastroenterol.12(34), 5473 (2006).
   PubMed Web of Science ®Google Scholar
• Hull MA . Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?Eur. J. Cancer41(13), 1854–1863 (2005).
   PubMed Web of Science ®Google Scholar
• Baandrup L . Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer – a nationwide case-control study. Ann. Oncol.26, 787–792 (2015).
   PubMedGoogle Scholar
• Pereira C , QueirósS , GalagharA et al. Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development. PLoS ONE9(4), e92000 (2014).
   PubMed Web of Science ®Google Scholar
• Díaz-Cruz ES , BrueggemeierRW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med. Chem.6(3), 221–232 (2006).
   PubMedGoogle Scholar
• Thun MJ , JacobsEJ , PatronoC. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol.9(5), 259 (2012).
   PubMed Web of Science ®Google Scholar
• Cuzick J , OttoF , BaronJAet al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol.10(5), 501–507 (2009).
   PubMed Web of Science ®Google Scholar
• Patrignani P , PatronoC. Aspirin and cancer. J. Am. Coll. Cardiol.68(9), 967–976 (2016).
   PubMed Web of Science ®Google Scholar
• Grinstein J , CannonCP. Aspirin resistance: current status and role of tailored therapy. Clin. Cardiol.35(11), 673–680 (2012).
   PubMed Web of Science ®Google Scholar
• Navaratnam K , AlfirevicA , AlfirevicZ. Low dose aspirin and pregnancy: how important is aspirin resistance?BJOG123(9), 1481–1487 (2016).
   PubMed Web of Science ®Google Scholar
• Kuliczkowski W , WitkowskiA , PolonskiLet al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J.30(4), 426–435 (2009).
   PubMed Web of Science ®Google Scholar
• Abacı O , KılıçkesmezKO. Aspirin resistance: where are we now. Anadolu Kardiyol. Derg.13(4), 370–373 (2013).
   PubMedGoogle Scholar
• Mason PJ , JacobsAK , FreedmanJE. Aspirin resistance and atherothrombotic disease. J. Am. Coll. Cardiol.46(6), 986–993 (2005).
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M , PharandC , SchampaertE , TurgeonJ , PalisaitisDA , DiodatiJG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J.28(14), 1702–1708 (2007).
   PubMed Web of Science ®Google Scholar
• Pulcinelli FM , RiondinoS. More on: aspirin resistance: position paper of the Working Group on Aspirin Resistance. Proposal for a laboratory test guiding algorithm. J. Thromb. Haemost.4(2), 485–487 (2006).
   PubMed Web of Science ®Google Scholar
• Weber A-A , PrzytulskiB , SchanzA , HohlfeldT , SchrörK. Towards a definition of aspirin resistance: a typological approach. Platelets13(1), 37–40 (2002).
   PubMed Web of Science ®Google Scholar
• Hankey GJ , EikelboomJW. Aspirin resistance. Lancet367(9510), 606–617 (2006).
   PubMed Web of Science ®Google Scholar
• Gum PA , Kottke-MarchantK , PoggioEDet al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol.88(3), 230–235 (2001).
   PubMed Web of Science ®Google Scholar
• Schwartz KA , SchwartzDE , GhoshehK , ReevesMJ , BarberK , DefrancoA. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am. J. Cardiol.95(8), 973–975 (2005).
   PubMed Web of Science ®Google Scholar
• Roy P , BonelloL , TorgusonRet al. Impact of “nuisance” bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am. J. Cardiol.102(12), 1614–1617 (2008).
   PubMed Web of Science ®Google Scholar
• Kojuri J , MahmoodyY , SabeghBZ , JannatiM , MahboodiA , KhaliliA. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting. Cardiovasc. Ther.28(3), 147–152 (2010).
   PubMed Web of Science ®Google Scholar
• Peters RJ , MehtaSR , FoxKAet al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation108(14), 1682–1687 (2003).
   PubMed Web of Science ®Google Scholar
• Trialists’ Collaboration A . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ324(7329), 71–86 (2002).
   PubMedGoogle Scholar
• Cotter G , ShemeshE , ZehaviMet al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am. Heart J. 147(2), 293–300 (2004).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , BeckerRC , MannKG , SteinhublSR , MichelsonAD. Platelet function monitoring in patients with coronary artery disease. J. Am. Coll. Cardiol.50(19), 1822–1834 (2007).
   PubMed Web of Science ®Google Scholar
• Feher G , KoltaiK , PappEet al. Aspirin resistance. Drugs Aging23(7), 559–567 (2006).
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F , ReillyMP , KapoorSCet al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med.345(25), 1809–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Tran HA , AnandSS , HankeyGJ , EikelboomJW. Aspirin resistance. Thromb. Res.120(3), 337–346 (2007).
   PubMed Web of Science ®Google Scholar
• Pulcinelli FM , PignatelliP , CelestiniA , RiondinoS , GazzanigaPP , VioliF. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J. Am. Coll. Cardiol.43(6), 979–984 (2004).
   PubMed Web of Science ®Google Scholar
• Fitzgerald R , PirmohamedM. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol. Ther.130(2), 213–225 (2011).
   PubMed Web of Science ®Google Scholar
• Bonaterra GA , HildebrandtW , BodensAet al. Increased cyclooxygenase-2 expression in peripheral blood mononuclear cells of smokers and hyperlipidemic subjects. Free Radic. Biol. Med.38(2), 235–242 (2005).
   PubMed Web of Science ®Google Scholar
• Penglis PS , ClelandLG , DemasiM , CaugheyGE , JamesMJ. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J. Immunol.165(3), 1605–1611 (2000).
   PubMed Web of Science ®Google Scholar
• Frelinger Iii AL , FurmanMI , LindenMDet al. Clinical perspective. Circulation113(25), 2888–2896 (2006).
   PubMed Web of Science ®Google Scholar
• Ertugrul DT , TutalE , YıldızMet al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J. Clin. Endocrinol. Metabol.95(6), 2897–2901 (2010).
   PubMed Web of Science ®Google Scholar
• Faraday N , YanekLR , MathiasRet al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation115(19), 2490–2496 (2007).
   PubMed Web of Science ®Google Scholar
• Yi X , HanZ , ZhouQ , LinJ , WangC. Interactions among COX-2, GPIIIa and P2Y1 variants are associated with aspirin responsiveness and adverse events in patients with ischemic stroke. Ther. Adv. Neurol. Disord.10(3), 161–170 (2017).
   PubMed Web of Science ®Google Scholar
• Goodman T , SharmaP , FerroA. The genetics of aspirin resistance. Int. J. Clin. Pract.61(5), 826–834 (2007).
   PubMed Web of Science ®Google Scholar
• Brookes AJ . The essence of SNPs. Gene234(2), 177–186 (1999).
   PubMed Web of Science ®Google Scholar
• Shastry BS . SNP alleles in human disease and evolution. J. Hum. Genet.47(11), 561 (2002).
   PubMed Web of Science ®Google Scholar
• Monzo M , NavarroA , FerrerG , ArtellsR. Pharmacogenomics: a tool for improving cancer chemotherapy. Clin. Transl. Oncol.10(10), 628–637 (2008).
   PubMed Web of Science ®Google Scholar
• Bush WS , MooreJH. Genome-wide association studies. PLoS Comput. Biol.8(12), e1002822 (2012).
   PubMed Web of Science ®Google Scholar
• Reich DE , LanderES. On the allelic spectrum of human disease. Trends Genet.17(9), 502–510 (2001).
   PubMed Web of Science ®Google Scholar
• Wang WY , BarrattBJ , ClaytonDG , ToddJA. Genome-wide association studies: theoretical and practical concerns. Nat. Rev. Genet.6(2), 109 (2005).
   PubMed Web of Science ®Google Scholar
• Patnala R , ClementsJ , BatraJ. Candidate gene association studies: a comprehensive guide to useful in silico tools. BMC Genet.14(1), 39 (2013).
   PubMed Web of Science ®Google Scholar
• Kwon JM , GoateAM. The candidate gene approach. Alcohol Res. Health.24(3), 164–168 (2000).
   PubMedGoogle Scholar
• Collins FS , GuyerMS , ChakravartiA. Variations on a theme: cataloging human DNA sequence variation. Science278(5343), 1580–1581 (1997).
   PubMed Web of Science ®Google Scholar
• Manolio TA . Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med.363(2), 166–176 (2010).
   PubMed Web of Science ®Google Scholar
• Manolio TA , BrooksLD , CollinsFS. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest.118(5), 1590–1605 (2008).
   PubMed Web of Science ®Google Scholar
• Patel JN , McLeodHL , InnocentiF. Implications of genome-wide association studies in cancer therapeutics. Br. J. Clin. Pharmacol.76(3), 370–380 (2013).
   PubMed Web of Science ®Google Scholar
• Hirschhorn JN , DalyMJ. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet.6(2), 95 (2005).
   PubMed Web of Science ®Google Scholar
• Gabriel SB , SchaffnerSF , NguyenHet al. The structure of haplotype blocks in the human genome. Science296(5576), 2225–2229 (2002).
   PubMed Web of Science ®Google Scholar
• Pearson TA , ManolioTA. How to interpret a genome-wide association study. JAMA299(11), 1335–1344 (2008).
   PubMed Web of Science ®Google Scholar
• Visscher PM , BrownMA , McCarthyMI , YangJ. Five years of GWAS discovery. Am. J. Hum. Genet.90(1), 7–24 (2012).
   PubMed Web of Science ®Google Scholar
• Alghamdi J , PadmanabhanS. Fundamentals of complex trait genetics and association studies. In: Handbook of Pharmacogenomics and Stratified Medicine. 1 ed., Academic Press, London, UK, PadmanabhanS (Ed.) 235–257 (2014).
   Google Scholar
• Pasche B , YiN. Candidate gene association studies: successes and failures. Curr. Opin. Genet. Dev.20(3), 257–261 (2010).
   PubMed Web of Science ®Google Scholar
• Gallego-Fabrega C , KrupinskiJ , Fernandez-CadenasI , ParaEl Estudio Genético CE ; GenestrokeConsortium. Drug resistance and secondary treatment of ischaemic stroke: the genetic component of the response to acetylsalicylic acid and clopidogrel. Neurología30(9), 566–573 (2015).
   PubMed Web of Science ®Google Scholar
• Postuła M , Tarchalska-KryńskaB , FilipiakKJet al. Factors responsible for “aspirin resistance” – can we identify them? Kardiol. Pol. 68(4), 410–418 (2010).
   Web of Science ®Google Scholar
• Maree A , CurtinR , ChubbAet al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J. Thromb. Haemost.3(10), 2340–2345 (2005).
   PubMed Web of Science ®Google Scholar
• Halushka MK , WalkerLP , HalushkaPV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin. Pharmacol. Ther.73(1), 122–130 (2003).
   PubMed Web of Science ®Google Scholar
• Lepäntalo A , MikkelssonJ , ReséndizJCet al. Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb. Haemost.95(02), 253–259 (2006).
   PubMedGoogle Scholar
• Yi X , ZhouQ , LinJ , ChiL , HanZ. Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C. J. Atheroscler. Thromb.14092 (2012).
   Web of Science ®Google Scholar
• Pettinella C , RomanoM , StuppiaL , SantilliF , LianiR , DavìG. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb. Haemost.101(04), 687–690 (2009).
   PubMedGoogle Scholar
• Papafili A , HillMR , BrullDJet al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol.22(10), 1631–1636 (2002).
   PubMed Web of Science ®Google Scholar
• Sharma V , KaulS , Al-HazzaniA , AlshatwiAA , JyothyA , MunshiA. Association of COX-2 rs20417 with aspirin resistance. J. Thromb. Thrombolysis.35(1), 95–99 (2013).
   PubMed Web of Science ®Google Scholar
• Pereira C , MedeirosRM , Dinis-RibeiroMJ. Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available?Eur. J. Gastroenterol. Hepatol.21(1), 76–91 (2009).
   PubMed Web of Science ®Google Scholar
• Weng Z , LiX , LiY , LinJ , PengF , NiuW. The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS ONE8(11), e78093 (2013).
   PubMed Web of Science ®Google Scholar
• Wang H , SunX , DongWet al. Association of GPI a and COX-2 gene polymorphism with aspirin resistance. J. Clin. Lab. Anal.32(4), e22331 (2018).
   PubMed Web of Science ®Google Scholar
• Szczeklik A , UndasA , SanakM , FrołowM , WęgrzynW. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br. J. Haematol.110(4), 965–967 (2000).
   PubMed Web of Science ®Google Scholar
• Cooke GE , Liu-StrattonY , FerketichAKet al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J. Am. Coll. Cardiol.47(3), 541–546 (2006).
   PubMed Web of Science ®Google Scholar
• Lim E , CarballoS , CornelissenJet al. Dose-related efficacy of aspirin after coronary surgery in patients with PlA2 polymorphism (NCT00262275). Ann. Thorac. Surg.83(1), 134–138 (2007).
   PubMed Web of Science ®Google Scholar
• Abderrazek F , ChakrounT , AddadFet al. The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb. Res.125(6), e265–e268 (2010).
   PubMed Web of Science ®Google Scholar
• Würtz M , NissenPH , GroveEL , KristensenSD , HvasA-M. Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1. PLoS ONE9(10), e111816 (2014).
   PubMed Web of Science ®Google Scholar
• Watson SP , GibbinsJ. Collagen receptor signalling in platelets: extending the role of the ITAM. Immunol. Today19(6), 260–264 (1998).
   PubMedGoogle Scholar
• Du G , LinQ , WangJ. A brief review on the mechanisms of aspirin resistance. Int. J. Cardiol.220, 21–26 (2016).
   PubMed Web of Science ®Google Scholar
• Wurtz M , KristensenSD , HvasAM , GroveEL. Pharmacogenetics of the antiplatelet effect of aspirin. Curr. Pharm. Des.18(33), 5294–5308 (2012).
   PubMed Web of Science ®Google Scholar
• Su G , WangZ , DingY , LiuX , WangJ. Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J. Huazhong. Univ. Sci. Technolog. Med. Sci.27(6), 664–667 (2007).
   PubMedGoogle Scholar
• Ulehlova J , SlavikL , KucerovaJ , KrcovaV , VaclavikJ , IndrakK. Genetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy. Genet. Test. Mol. Biomarkers18(9), 599–604 (2014).
   PubMed Web of Science ®Google Scholar
• Johnson AD , YanekLR , ChenM-Het al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat. Genet.42(7), 608 (2010).
   PubMed Web of Science ®Google Scholar
• Luo G-P , NiB , YangX , WuY-Z. von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol.128(3), 158–169 (2012).
   PubMed Web of Science ®Google Scholar
• Wurtz M , LordkipanidzeM , GroveE. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. J. Thromb. Haemost.11(9), 1627–1639 (2013).
   PubMed Web of Science ®Google Scholar
• Maguire JM , ThakkinstianA , SturmJet al. Polymorphisms in platelet glycoprotein 1bα and factor VII and risk of ischemic stroke: a meta-analysis. Stroke39(6), 1710–1716 (2008).
   PubMed Web of Science ®Google Scholar
• Fujiwara T , IkedaM , EsumiKet al. Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J.7(6), 395 (2007).
   PubMed Web of Science ®Google Scholar
• Gieger C , RadhakrishnanA , CvejicAet al. New gene functions in megakaryopoiesis and platelet formation. Nature480(7376), 201 (2011).
   PubMed Web of Science ®Google Scholar
• Kamatani Y , MatsudaK , OkadaYet al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat. Genet.42(3), 210 (2010).
   PubMed Web of Science ®Google Scholar
• Higuchi W , FuseI , HattoriA , AizawaY. Mutations of the platelet thromboxane A2 (TXA2) receptor in patients characterized by the absence of TXA2-induced platelet aggregation despite normal TXA2 binding activity. Thromb. Haemost.82(11), 1528–1531 (1999).
   PubMedGoogle Scholar
• Peng L-L , ZhaoY-Q , ZhouZ-Yet al. Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Acta Pharmacol. Sin.37(11), 1442 (2016).
   PubMed Web of Science ®Google Scholar
• Postula M , Kaplon-CieslickaA , RosiakMet al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J. Thromb. Haemost.9(11), 2291–2301 (2011).
   PubMed Web of Science ®Google Scholar
• Jefferson BK , FosterJH , McCarthyJJet al. Aspirin resistance and a single gene. Am. J. Cardiol.95(6), 805–808 (2005).
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M , DiodatiJG , PalisaitisDA , SchampaertE , TurgeonJ , PharandC. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb. Res.128(1), 47–53 (2011).
   PubMed Web of Science ®Google Scholar
• Timur AA , MurugesanG , ZhangLet al. P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. Int. J. Lab. Hematol.34(5), 473–483 (2012).
   PubMed Web of Science ®Google Scholar
• Undas A , SydorWJ , BrummelK , MusialJ , MannKG , SzczeklikA. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation107(1), 17–20 (2003).
   PubMed Web of Science ®Google Scholar
• Pamukcu B , OflazH , OnurI , HancerV , YavuzS , NisanciY. Impact of genetic polymorphisms on platelet function and aspirin resistance. Blood Coagul. Fibrinolysis.21(1), 53–56 (2010).
   PubMed Web of Science ®Google Scholar
• Kauskot A , VandenbrieleC , LouwetteSet al. PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway. Blood121(26), 5208–5217 (2013).
   PubMed Web of Science ®Google Scholar
• Kauskot A , DiMichele M , LoyenS , FresonK , VerhammeP , HoylaertsMF. A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1. Blood119(17), 4056–4065 (2012).
   PubMed Web of Science ®Google Scholar
• Faraday N , YanekLR , YangXPet al. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood118(12), 3367–3375 (2011).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR , BhattDL , BrennanDMet al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann. Intern. Med.150(6), 379–386 (2009).
   PubMed Web of Science ®Google Scholar
• Kasmeridis C , ApostolakisS , LipGY. Aspirin and aspirin resistance in coronary artery disease. Curr. Opin. Pharmacol.13(2), 242–250 (2013).
   PubMed Web of Science ®Google Scholar
• Rocca B , DraganiA , PagliacciaF. Identifying determinants of variability to tailor aspirin therapy. Expert Rev. Cardiovasc. Ther.11(3), 365–379 (2013).
   PubMedGoogle Scholar
• Lev EI , SolodkyA , HarelNet al. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J. Am. Coll. Cardiol.55(2), 114–121 (2010).
   PubMed Web of Science ®Google Scholar
• Beitelshees AL , VooraD , LewisJP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers. Med.8, 43 (2015).
   PubMed Web of Science ®Google Scholar
• Paseban M , MarjanehRM , BanachM , RiahiMM , BoS , SahebkarA. Modulation of microRNAs by aspirin in cardiovascular disease. Trends Cardiovasc. Med. (2019) ( In press).
   PubMed Web of Science ®Google Scholar